title: Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.
abstract: BACKGROUND
  It can be hypothesised that inherited polymorphisms in the drug-transporter ABCB1 gene may interfere with interindividual variations in drug response in breast cancer patients. Docetaxel is a substrate for ABCB1 whose function has been shown to be modulated by oestrogen and progesterone.
  
  
  METHODS
  Whether ABCB1 polymorphisms including T-129C, A61G, C1236T, G2677T/A and C3435T polymorphisms could account for variations in the disposition of docetaxel and whether menopausal status at the time of diagnosis might interact with this effect were analysed in women receiving neoadjuvant chemotherapy for breast cancer (n=86).
  
  
  RESULTS
  A highly significant association was observed, but restricted to premenopausal women (n=53), between the pharmacokinetics of docetaxel and C3435T polymorphism, as patients with CC genotype had lower mean values of the area under the plasma concentration-time curve (AUC) of docetaxel than patients with CT and TT genotypes (P<0.0001). Comparison between pre- and postmenopausal women with the same C3435T genotype yielded a significant difference in docetaxel AUC only for CC genotype (P<0.0001).
  
  
  CONCLUSIONS
  These results suggest that C3435T polymorphism genotyping and menopausal status at the time of diagnosis might be useful when considering chemotherapy regimens including docetaxel in breast cancer patients.
authors.affiliation: Service d'Histologie-Biologie Tumorale, hôpital Tenon, AP-HP, ER2 UPMC Université Pierre et Marie Curie, 4 rue de la Chine, Paris 75020, France. anne.fajac@tnn.aphp.fr
authors.forename: A
authors.initials: A
authors.lastname: Fajac
authors.forename: J
authors.initials: J
authors.lastname: Gligorov
authors.forename: K
authors.initials: K
authors.lastname: Rezai
authors.forename: P
authors.initials: P
authors.lastname: Lévy
authors.forename: E
authors.initials: E
authors.lastname: Lévy
authors.forename: F
authors.initials: F
authors.lastname: Selle
authors.forename: K
authors.initials: K
authors.lastname: Beerblock
authors.forename: D
authors.initials: D
authors.lastname: Avenin
authors.forename: P
authors.initials: P
authors.lastname: Saintigny
authors.forename: S
authors.initials: S
authors.lastname: Hugonin
authors.forename: J-F
authors.initials: JF
authors.lastname: Bernaudin
authors.forename: F
authors.initials: F
authors.lastname: Lokiec
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011110:Polymorphism, Genetic; D017698:Postmenopause; D017697:Premenopause; D043823:Taxoids / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel